Dealmaking and Industry Outlook: Autoimmune and Inflammatory Diseases

Published by	Decision Resources, Inc.
Published	July, 2009	Product code	95542
Content info	43 Prices
Price	US $ 3450 PDF by E-mail (Global License)

Introduction
Related Reports

Dealmaking and Industry Outlook: Autoimmune and Inflammatory Diseases published by Decision Resources, Inc. in July, 2009. This report consists of 43 Prices and the price starts from US $ 3450.

Introduction

Abstract

Featuring an analysis of more than 200 deals in this therapy area for 2007, 2008, and the fi rst fi ve months of 2009

Introduction

Better diagnostics, the means to treat earlier stage-disease, disease-modifying therapies, and disease prevention are the holy grails of autoimmune and infl ammatory disease drug development. However, basic science and redundant biological pathways are holding back this therapy area. In this report, we investigate the autoimmune and infl ammatory disease industry. We analyze 200 deals in this therapy area for 2007, 2008, and the fi rst fi ve months of 2009. We assess what types of deals companies are executing and what business strategies they are deploying for future success. We discuss recent industry-shaping events, industry drivers, and barriers that are holding back this therapy area.

Questions Answered in This Report

Analyzing deals opens up a window to a company' s business strategies. What do the 200 deals related to autoimmune and infl ammatory diseases that took place in 2007, 2008, and the fi rst fi ve months of 2009 indicate about the business strategies of Big Biotech, Mid-Size Pharma, and Big Pharma? What technologies are hot? What new targets were licensed or optioned?
Three mega-mergers were announced in early 2009. What impact will these deals have on this therapy area? Why did Pfi zer CEO Jeffrey Kindler think that Wyeth was the right answer for Pfi zer? What trouble might Merck & Co. Have with the Schering-Plough acquisition? What might prevent Roche from achieving its goals in its acquisition of Genentech?
The number of generics and branded generics is rising in some segments of this therapy area. Which diseases are seeing an increase in these types of agents and why? What do GlaxoSmithKline' s recent deals with Aspen Pharmacare and Dr Reddy' s Laboratories indicate about this company' s current strategies?
Understanding biological pathways and discovering biomarkers is key to future success in the autoimmune and infl ammatory disease markets. What are the hurdles in this arena? What recent deals took place relating to pharmacogenomics? What gene discoveries may help in at least one disease area?
Companies have a continued passion for biologics. What are the recent deals in this area? What are the 16 licensed Mabs? The 11 recombinant proteins? The 8 peptides?
Companies are scouring early-stage technology opportunities for breakthrough technologies and innovative product candidates. What are the top fi ve most licensed technologies in our study period? What 37 nonbiologics product deals took place? What were the 16 new targets?

Scope

Therapy area: Diseases; market size, top 25 companies by worldwide sales, major brands.
200 deals: Total deal volume; biobucks; 20 largest deals; Big Biotech, Mid-Size Pharma and Big Pharma deals; most active disease areas; most active companies; top fi ve deals by technology, outlicensing, divesting, new targets, biological pathways; nucleic acid therapeutics; budesonide deals; reformulations; inhaler issues; combination products.
Business strategies: Inlicensing, outlicensing, divesting low priority R&D programs, targeted acquisitions, benefi ts of a portfolio of modest products, milestone-driven dealmaking, shared development risk, emerging markets, generics markets, branded generics, life-cycle management, optimizing the commercialization of off-patent drugs, a passion for biologics, drug recycling and reformulations, fi xed-dose combinations.
Industry-shaping events: Big Pharma consolidation, market entry, safety issues, change of ownership issues, reverse mergers, tumor necrosis factor-alpha (TNF-α) blockers, biotech' s fi nancial crisis.
Industry outlook: Ten therapy area drivers; factors holding back this therapy area; annual growth rates for specifi c disease areas; three events that will invigorate the therapy area; two key harbingers of trouble to come.

Executive Summary
- Strategic Considerations
- Stakeholder Implications
Importance of the Underlying Biology
Industry Size and Major Players
Analysis of 200 Deals
- Deal Volume
- Largest Deals
- Big Biotech, Mid-Size Pharma, and Big Pharma Deal Volumes
- Deals By Disease Category
- Types of Deals
- Big Biotech Looking for Money and Products
- Nonbiologic Product Deals
- Nucleic Acid Technology Deals
Business Strategies
- King of Targeted Dealmaking
- Company Acquisitions: Maybe Not
- Divesting: Better Focus and Commercialization
- Passion for Biologics
- Drug Recycling
  - Budesonide Story
  - Drug Combination
- Industry-Shaping Events, 2008-2009
  - Impact of Big Pharma Consolidation
  - Safety Concerns
  - Biotech Is Hurting
- Industry Drivers
- Ten Drivers of the Autoimmune and Infl ammatory Disease Therapy Area
- Factors Holding Back the Autoimmune and Infl ammatory Disease Industry
Industry Outlook

Tables

1. Decision Resources Analysts' Input on the Current Status and Future Directions of Autoimmune and Infl ammatory Disease Therapies
2. Autoimmune and Infl ammatory Diseases: Nonbiologic Product Deals, 2007-2009
3. Autoimmune and Infl ammatory Diseases: Nucleic Acid Therapeutics Deals, 2007-2009
4. Autoimmune and Infl ammatory Diseases: Antibody Deals, 2007-2009
5. Autoimmune and Infl ammatory Diseases: Peptide and Recombinant Protein Deals, 2007-2009
6. Autoimmune and Infl ammatory Diseases: Drug Delivery and Formulation Technology Deals, 2007-2009 .

Figures

1. Autoimmune and Infl ammatory Diseases: Top 25 Companies by Worldwide Sales, 2008 and 2014
2. Autoimmune and Infl ammatory Diseases: Deal Volume Based on Potential Deal Size, 2007-2009
3. Autoimmune and Infl ammatory Diseases: the Largest Deals, 2007-2009
4. Autoimmune and Infl ammatory Diseases: Big Pharma, Mid-Size Pharma, and Big Biotech Deal Volume, 2007-2009
5. Deals in the Autoimmune and Infl ammatory Therapy Area by Categories of Disease, 2007-2009
6. Types of Autoimmune and Infl ammatory Disease Deals, 2007-2009
7. NF-KB Pathway
8. Development Timeline for the Tumor Necrosis Factor-Alpha Blocker Humira (adalimumab)